Your browser doesn't support javascript.
loading
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo, José; Subbiah, Vivek; Besse, Benjamin; Moreno, Victor; López, Rafael; Sala, María Angeles; Peters, Solange; Ponce, Santiago; Fernández, Cristian; Alfaro, Vicente; Gómez, Javier; Kahatt, Carmen; Zeaiter, Ali; Zaman, Khalil; Boni, Valentina; Arrondeau, Jennifer; Martínez, Maite; Delord, Jean-Pierre; Awada, Ahmad; Kristeleit, Rebecca; Olmedo, Maria Eugenia; Wannesson, Luciano; Valdivia, Javier; Rubio, María Jesús; Anton, Antonio; Sarantopoulos, John; Chawla, Sant P; Mosquera-Martinez, Joaquín; D'Arcangelo, Manolo; Santoro, Armando; Villalobos, Victor M; Sands, Jacob; Paz-Ares, Luis.
  • Trigo J; Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Málaga, Spain. Electronic address: jmtrigo@seom.org.
  • Subbiah V; MD Anderson Cancer Center, Houston, TX, USA.
  • Besse B; Gustave Roussy Cancer Campus, Villejuif, France; Paris Sud University, Orsay, France.
  • Moreno V; START Madrid-Fundación Jiménez Díaz, Hospital Fundación Jiménez Díaz, Madrid, Spain.
  • López R; Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
  • Sala MA; Organización Sanitaria Integrada Bilbao Basurto, Bilbao, Spain.
  • Peters S; University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Ponce S; Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
  • Fernández C; Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.
  • Alfaro V; Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.
  • Gómez J; Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.
  • Kahatt C; Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.
  • Zeaiter A; Pharma Mar, Clinical Research and Development, Colmenar Viejo, Madrid, Spain.
  • Zaman K; University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Boni V; START Madrid-Centro Integral Oncológico Clara Campal, Hospital Universitario Sanchinarro, Madrid, Spain.
  • Arrondeau J; Hôpital Cochin, Paris, France.
  • Martínez M; Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Delord JP; Institut Claudius Regaud, Toulouse, France.
  • Awada A; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Kristeleit R; University College London Cancer Institute, London, UK.
  • Olmedo ME; Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Wannesson L; Ospedale San Giovanni, Bellinzona, Switzerland.
  • Valdivia J; Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Rubio MJ; Hospital Universitario Reina Sofía, Cordoba, Spain.
  • Anton A; Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Sarantopoulos J; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, MD Anderson Cancer Center, San Antonio, TX, USA.
  • Chawla SP; Sarcoma Oncology Center, Santa Monica, CA, USA.
  • Mosquera-Martinez J; Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • D'Arcangelo M; Ospedale Santa Maria delle Croci, Ravenna, Italy.
  • Santoro A; Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Villalobos VM; University of Colorado Cancer Center, Aurora, CO, USA.
  • Sands J; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Paz-Ares L; Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense de Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.
Lancet Oncol ; 21(5): 645-654, 2020 05.
Article en En | MEDLINE | ID: mdl-32224306

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carbolinas / Carcinoma Pulmonar de Células Pequeñas / Compuestos Heterocíclicos de 4 o más Anillos / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carbolinas / Carcinoma Pulmonar de Células Pequeñas / Compuestos Heterocíclicos de 4 o más Anillos / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2020 Tipo del documento: Article